Efficacy and safety of risperidone for attention deficit hyperactivity disorder and disruptive behaviour disorders: a systematic review and meta-analysis - PubMed

6 hours ago

Risperidone augmentation significantly reduces aggression in children and adolescents with ADHD and comorbid disruptive behavior disorders, with a standardized mean difference of -0.79.
The treatment is associated with adverse effects, including notable weight gain (2.1 kg vs. 0.5 kg in controls) and significantly elevated serum prolactin levels (28.5 ng/mL vs. 2.3 ng/mL).
The meta-analysis was based on three randomized controlled trials involving 279 participants aged 6 to 12 years, highlighting both the efficacy and safety concerns of risperidone use in this population.

Hasty Briefsbeta